Leukemia, Acute Lymphoblastic 3 (ALL3)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 57
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 57 29 6 39 70
Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 70
Precursor B-Cell Acute Lymphoblastic Leukemia 58
Precursor B-Cell Acute Lymphocytic Leukemia 58
Precursor B-Cell Lymphoblastic Leukemia 70
Burkitt Lymphoma 70
B-All 58
All3 57


Orphanet: 58  
Rare haematological diseases

External Ids:

OMIM® 57 615545
ICD10 via Orphanet 33 C83.5 C91.0
UMLS via Orphanet 71 C0006413 C1292769
Orphanet 58 ORPHA99860
UMLS 70 C0006413 C0023485 C1292769 more

Summaries for Leukemia, Acute Lymphoblastic 3

MalaCards based summary : Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to b-lymphoblastic leukemia/lymphoma with bcr-abl1 and b-lymphoblastic leukemia/lymphoma, bcr-abl1-like, and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vindesine and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

More information from OMIM: 615545

Related Diseases for Leukemia, Acute Lymphoblastic 3

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma with bcr-abl1 32.0 KMT2A ABL1
2 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 31.8 IKZF1 FOXP1 CDKN2A ABL1
3 b-lymphoblastic leukemia/lymphoma with hypodiploidy 31.7 TCF3 PBX1 ETV6 ABL1
4 b-lymphoblastic leukemia/lymphoma with iamp21 31.1 PBX1 PAX5 KMT2A IKZF1 ETV6 ABL1
5 b-lymphoblastic leukemia/lymphoma 31.0 TCF3 PBX1 PAX5 KMT2A IGH FLT3
6 monocytic leukemia 30.4 RUNX1 KMT2A FLT3
7 t-cell acute lymphoblastic leukemia 30.4 RUNX1 IKZF1 GATA3 FLT3 ETV6 CDKN2A
8 central nervous system leukemia 29.9 KMT2A AFF1 ABL1
9 mental retardation, autosomal dominant 29 29.9 PBX1 ABL1
10 myeloproliferative neoplasm 29.7 RUNX1 PDGFRA KMT2A FLT3 ETV6 BCR
11 leukemia, acute lymphoblastic 29.6 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
12 b-cell lymphoma 29.6 PAX5 IKZF1 IGH FOXP1 CDKN2A BCR
13 myeloid leukemia 29.6 RUNX1 KMT2A FLT3 ETV6 BCR ABL1
14 mixed phenotype acute leukemia 29.5 RUNX1 KMT2A FLT3 ABL1
15 myelodysplastic syndrome 29.5 RUNX1 KMT2A FLT3 ETV6 CDKN2A ABL1
16 b-cell adult acute lymphocytic leukemia 29.4 PBX1 IKZF1 BCR ABL1
17 hematologic cancer 29.3 RUNX1 PAX5 KMT2A IKZF1 FLT3 ETV6
18 leukemia, chronic lymphocytic 29.3 PAX5 KMT2A IGH FLT3 BCR ABL1
19 acute leukemia 29.2 TCF3 RUNX1 PBX1 PAX5 KMT2A FLT3
20 adult acute lymphocytic leukemia 29.1 TCF3 PBX1 PAX5 IKZF1 ETV6 AFF1
21 precursor t-cell acute lymphoblastic leukemia 29.1 KMT2A IKZF1 IGH FLT3 ETV6 CDKN2A
22 childhood b-cell acute lymphoblastic leukemia 29.0 RUNX1 PIP4K2A PAX5 IKZF1 GATA3 CDKN2A
23 leukemia, chronic myeloid 28.6 RUNX1 PDGFRA KMT2A IKZF1 FLT3 ETV6
24 childhood leukemia 28.6 TCF3 RUNX1 PBX1 KMT2A ETV6 CDKN2A
25 leukemia 28.0 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
26 childhood acute lymphocytic leukemia 27.8 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
27 leukemia, acute myeloid 27.6 TCF3 RUNX1 PDGFRA PBX1 PAX5 KMT2A
28 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 11.3
29 b-lymphoblastic leukemia/lymphoma kmt2a rearranged 11.1
30 b-lymphoblastic leukemia/lymphoma with etv6-runx1 11.1
31 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 11.1
32 b-lymphoblastic leukemia/lymphoma with il3-igh 11.1
33 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.1
34 hemophagocytic lymphohistiocytosis 10.5
35 sarcoma 10.4
36 spindle cell sarcoma 10.4
37 histiocytic sarcoma 10.4
38 philadelphia-negative chronic myeloid leukemia 10.4 BCR ABL1
39 pancytopenia 10.3
40 ring chromosome 21 10.3 KMT2A ETV6
41 ring chromosome 10.3 KMT2A ETV6
42 primary hypereosinophilic syndrome 10.2 PDGFRA ETV6
43 cytogenetically normal acute myeloid leukemia 10.2 KMT2A FLT3
44 testicular leukemia 10.2 ETV6 ABL1
45 burkitt lymphoma 10.2
46 laryngeal small cell carcinoma 10.2 PDGFRA CDKN2A
47 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.2 RUNX1 FLT3
48 inverted transitional papilloma 10.2 GATA3 CDKN2A
49 autoimmune disease 10.2
50 leukemia, acute monocytic 10.2

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:

Diseases related to Leukemia, Acute Lymphoblastic 3

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

Clinical features from OMIM®:

615545 (Updated 05-Apr-2021)

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:

bone pain

GenomeRNAi Phenotypes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.98 BCR
2 Decreased viability GR00055-A-2 9.98 BCR
3 Decreased viability GR00173-A 9.98 FLT3 PDGFRA
4 Decreased viability GR00221-A-1 9.98 ABL1 CDKN2A FLT3 PDGFRA PIP4K2A
5 Decreased viability GR00221-A-2 9.98 ABL1 BCR
6 Decreased viability GR00221-A-3 9.98 ABL1 CDKN2A PDGFRA
7 Decreased viability GR00221-A-4 9.98 CDKN2A FLT3 PDGFRA PIP4K2A BCR
8 Decreased viability GR00249-S 9.98 PDGFRA BCR
9 Decreased viability GR00301-A 9.98 PIP4K2A BCR
10 Decreased viability GR00342-S-1 9.98 ABL1
11 Decreased viability GR00342-S-2 9.98 ABL1
12 Decreased viability GR00342-S-3 9.98 ABL1 BCR
13 Decreased viability GR00402-S-2 9.98 PDGFRA PIP4K2A BCR

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic 3:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
2 cellular MP:0005384 10.39 ABL1 AUTS2 BCR CDKN2A ETV6 FLT3
3 cardiovascular system MP:0005385 10.34 ABL1 AUTS2 CDKN2A ETV6 GATA3 HLF
4 hematopoietic system MP:0005397 10.32 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
5 mortality/aging MP:0010768 10.3 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
6 endocrine/exocrine gland MP:0005379 10.29 ABL1 AFF1 AUTS2 CDKN2A ETV6 FLT3
7 immune system MP:0005387 10.28 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
8 homeostasis/metabolism MP:0005376 10.27 ABL1 BCR CDKN2A ETV6 FLT3 GATA3
9 embryo MP:0005380 10.22 ABL1 AUTS2 CDKN2A ETV6 GATA3 KMT2A
10 digestive/alimentary MP:0005381 10.14 ABL1 BCR CDKN2A ETV6 GATA3 IKZF1
11 liver/biliary system MP:0005370 10.14 ABL1 AUTS2 BCR CDKN2A ETV6 HLF
12 nervous system MP:0003631 10.07 ABL1 AFF1 AUTS2 BCR CDKN2A GATA3
13 neoplasm MP:0002006 10.06 AUTS2 CDKN2A ETV6 FLT3 IKZF1 KMT2A
14 no phenotypic analysis MP:0003012 9.93 AFF1 AUTS2 CDKN2A ETV6 FLT3 GATA3
15 normal MP:0002873 9.73 ABL1 BCR ETV6 GATA3 HLF KMT2A
16 skeleton MP:0005390 9.32 ABL1 AUTS2 CDKN2A FLT3 GATA3 KMT2A

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
Polyestradiol phosphate Approved Phase 4 28014-46-2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
6 Anti-Retroviral Agents Phase 4
7 Anti-HIV Agents Phase 4
8 Reverse Transcriptase Inhibitors Phase 4
9 Hormone Antagonists Phase 4
10 Hormones Phase 4
11 Estradiol 3-benzoate Phase 4
12 Estradiol 17 beta-cypionate Phase 4
13 Estrogens Phase 4
14 Progestins Phase 4
rituximab Approved Phase 3 174722-31-7 10201696
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
Ifosfamide Approved Phase 3 3778-73-2 3690
Interferon beta-1b Approved Phase 3 145155-23-3
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
leucovorin Approved Phase 3 58-05-9 6006
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Mercaptopurine Approved Phase 3 50-44-2 667490
Blinatumomab Approved, Investigational Phase 3 853426-35-4
Etoposide Approved Phase 3 33419-42-0 36462
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Daunorubicin Approved Phase 3 20830-81-3 30323
Thioguanine Approved Phase 3 154-42-7 2723601
Ichthammol Approved Phase 3 8029-68-3
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
Cortisone Experimental Phase 3 53-06-5 222786

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone Completed NCT01940653 Phase 4 Progesterone
6 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
7 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
8 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
9 International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg Completed NCT00459667 Phase 3 Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046)
10 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101) Completed NCT01597778 Phase 3
11 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
12 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
13 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
14 A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine Sulfate
15 SPondyloArthritis: Inducing Drug-free Remission by Early TNF-Alpha bloCkade Under Guidance of Single Cell RNA Sequencing and Epigenetic Profiling. "The SPARTACUS Trial" Recruiting NCT04435288 Phase 3 week 24;week 36;Week 48;Week 60
16 Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
17 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
18 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Active, not recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
19 Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma Unknown status NCT01516593 Phase 2 Induction Phase;Consolidation Phase (on day +50);Intensification phase;BEAM conditioning
20 Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma Unknown status NCT01859819 Phase 2 Rituximab;IT Cytarabine
21 A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma Unknown status NCT01842672 Phase 1, Phase 2 Clofarabine;Mitoxantrone
22 Phase II Trial of CLAG-M in Relapsed ALL Unknown status NCT01513603 Phase 2 CLAG-M;CLAG-M
23 Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients Unknown status NCT03142646 Phase 1, Phase 2
24 A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604) Completed NCT00864227 Phase 2
25 A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603) Completed NCT00849147 Phase 2
26 A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment Completed NCT01116193 Phase 2 Lenalidomide plus dexamethasone
27 S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia Completed NCT00945815 Phase 2 clofarabine;cytarabine
28 Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma Completed NCT01290120 Phase 2 Chemotherapy-Rituximab combination
29 Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II Completed NCT00187161 Phase 2 Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
30 Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia Completed NCT00039130 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;prednisone;vincristine sulfate;Allopurinol
31 Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma Completed NCT00392834 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;liposomal cytarabine;methotrexate;therapeutic hydrocortisone;vincristine sulfate
32 Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) Completed NCT00388193 Phase 2 RITUXIMAB
33 A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy Completed NCT00057811 Phase 2 doxorubicin hydrochloride;cyclophosphamide;methotrexate;rasburicase;leucovorin calcium;prednisone;methylprednisolone;cytarabine;etoposide;vincristine sulfate;hydrocortisone sodium succinate
34 Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas Completed NCT00001237 Phase 2 granulocyte-macrophage colony stimulating factor (GM-CSF)
35 Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas Completed NCT00303953 Phase 2 belinostat
36 Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) Completed NCT00412243 Phase 1, Phase 2 Clofarabine;Cyclophosphamide
37 Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Completed NCT00669877 Phase 2 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;G-CSF;Cytarabine;Methotrexate
38 Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study. Completed NCT01219816 Phase 2 Epratuzumab;Epratuzumab
39 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
40 A Phase II Study of CCI-779 in B-cell Lymphoma and CLL Completed NCT00290472 Phase 2 temsirolimus
41 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
43 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
45 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
46 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
47 A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma Completed NCT00392990 Phase 2 Regimen A;Regimen B
48 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
49 A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas Completed NCT00058019 Phase 2 ixabepilone
50 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Genetic Tests for Leukemia, Acute Lymphoblastic 3

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to, 3 29 PAX5

Anatomical Context for Leukemia, Acute Lymphoblastic 3

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic 3:

T Cells, Bone, Bone Marrow, Liver, Myeloid, Eye, Prostate

Publications for Leukemia, Acute Lymphoblastic 3

Articles related to Leukemia, Acute Lymphoblastic 3:

(show all 21)
# Title Authors PMID Year
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 57 6
24013638 2013
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 57
30643249 2019
Head and Neck Cancer Complications in the Geriatric Population Based on Hospital Case Volume. 61
31170822 2021
Effect of purified fractions from cell culture supernate of high-density pre-B acute lymphoblastic leukemia cells (ALL3) on the growth of ALL3 cells at low density. 61
27804141 2017
AFM study shows prominent physical changes in elasticity and pericellular layer in human acute leukemic cells due to inadequate cell-cell communication. 61
27834315 2016
Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems. 61
27429840 2016
Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density. 61
27725845 2016
Adding the right (or left) twist to tris-chelate complexes--coordination chemistry of chiral oxazolylphenolates with M3+ ions (M = Al or lanthanide). 61
24201227 2014
Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). 61
18213709 2008
Evaluation of 2-methyl-3-hydroxy-4-pyridinecarboxylic acid as a possible chelating agent for iron and aluminium. 61
18354766 2008
Effects of low temperature on aluminum(III) hydrolysis: theoretical and experimental studies. 61
18817067 2008
Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. 61
16700036 2006
Extended coordination frameworks incorporating heterobimetallic squares. 61
15349164 2004
Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial). 61
14565657 2003
Symmetry of metal chelates. 61
11196787 2000
[Early appearance of myelodysplastic syndrome secondary to therapy for Burkitt-type acute lymphoblastic leukemia (ALL3)]. 61
10323104 1999
Chromatographic studies on a herb decoction. 61
22556839 1998
Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. 61
7833470 1995
Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. 61
1869243 1991
Collection of circulating stem cells and their use for autograft in adults with acute lymphoblastic leukaemia. 61
3057436 1988
[Acute lymphoblastic leukemia, Burkitt-cell type, after Hodgkin's disease. Study of 2 cases]. 61
3330607 1987

Variations for Leukemia, Acute Lymphoblastic 3

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PAX5 NM_016734.3(PAX5):c.547G>A (p.Gly183Ser) SNV risk factor 88892 rs398123063 GRCh37: 9:37002702-37002702
GRCh38: 9:37002705-37002705
2 PAX5 NM_016734.3(PAX5):c.1013-1G>A SNV Uncertain significance 517139 rs1554646594 GRCh37: 9:36846927-36846927
GRCh38: 9:36846930-36846930
3 PAX5 NM_016734.3(PAX5):c.1013-6A>G SNV Likely benign 802486 rs1587737218 GRCh37: 9:36846932-36846932
GRCh38: 9:36846935-36846935

Expression for Leukemia, Acute Lymphoblastic 3

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 3.

Pathways for Leukemia, Acute Lymphoblastic 3

GO Terms for Leukemia, Acute Lymphoblastic 3

Cellular components related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.97 TCF3 RUNX1 PIP4K2A PDGFRA PBX1 PAX5
2 protein-containing complex GO:0032991 9.8 TCF3 PDGFRA IKZF1 FLT3 CDKN2A BCR
3 chromatin GO:0000785 9.61 TCF3 RUNX1 PBX1 PAX5 IKZF1 HLF
4 nucleus GO:0005634 9.55 TCF3 RUNX1 PIP4K2A PDGFRA PBX1 PAX5

Biological processes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10 TCF3 RUNX1 PAX5 GATA3 FOXP1 ETV6
2 regulation of transcription by RNA polymerase II GO:0006357 9.97 TCF3 RUNX1 PBX1 PAX5 IKZF1 HLF
3 phosphorylation GO:0016310 9.93 PIP4K2A PDGFRA FLT3 CDKN2A BCR ABL1
4 regulation of transcription, DNA-templated GO:0006355 9.85 TCF3 RUNX1 PBX1 PAX5 KMT2A HLF
5 protein autophosphorylation GO:0046777 9.73 PDGFRA FLT3 BCR ABL1
6 positive regulation of endothelial cell migration GO:0010595 9.65 GATA3 FOXP1 ABL1
7 thymus development GO:0048538 9.58 PBX1 GATA3 ABL1
8 adrenal gland development GO:0030325 9.57 PDGFRA PBX1
9 positive regulation of histone H3-K4 methylation GO:0051571 9.56 KMT2A AUTS2
10 hematopoietic stem cell proliferation GO:0071425 9.55 RUNX1 ETV6
11 cell activation GO:0001775 9.54 PDGFRA GATA3
12 platelet-derived growth factor receptor signaling pathway GO:0048008 9.54 PDGFRA BCR ABL1
13 regulation of B cell receptor signaling pathway GO:0050855 9.51 RUNX1 PAX5
14 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.49 CDKN2A ABL1
15 embryonic hemopoiesis GO:0035162 9.43 PBX1 KMT2A GATA3
16 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 TCF3 RUNX1 PBX1 PAX5 KMT2A HLF
17 regulation of hematopoietic stem cell differentiation GO:1902036 9.35 TCF3 RUNX1 KMT2A GATA3 ABL1

Molecular functions related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.97 TCF3 RUNX1 PBX1 PAX5 HLF GATA3
2 kinase activity GO:0016301 9.91 PIP4K2A PDGFRA FLT3 CDKN2A BCR ABL1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 TCF3 RUNX1 PBX1 PAX5 IKZF1 HLF
4 sequence-specific double-stranded DNA binding GO:1990837 9.88 PBX1 HLF GATA3 FOXP1 ABL1
5 DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001227 9.8 TCF3 GATA3 FOXP1 ETV6
6 transcription factor binding GO:0008134 9.8 TCF3 RUNX1 PBX1 GATA3 CDKN2A
7 sequence-specific DNA binding GO:0043565 9.8 TCF3 PBX1 HLF GATA3 FOXP1 ETV6
8 DNA binding GO:0003677 9.73 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
9 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.7 TCF3 RUNX1 PBX1 PAX5 HLF GATA3
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.46 PDGFRA FLT3
11 DNA-binding transcription factor activity GO:0003700 9.28 TCF3 RUNX1 PBX1 PAX5 IKZF1 HLF

Sources for Leukemia, Acute Lymphoblastic 3

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....